COAG (Hemab Therapeutics Holdings) EBIT: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $46.52
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings EBIT?

Hemab Therapeutics Holdings COAG +3.48% 11 EBIT is $ Mil as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Hemab Therapeutics Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-70.12 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hemab Therapeutics Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was -1,240.65%. Hemab Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3,285.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Hemab Therapeutics Holdings  (NAS:COAG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hemab Therapeutics Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-70.119 * ( 1 - 0.35% )/( (5.378 + 5.886)/ 2 )
=-69.8735835/5.632
=-1,240.65 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=96.278 - 4.35 - ( 88.325 - max(0, 6.685 - 93.235+88.325))
=5.378

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=194.783 - 7.023 - ( 185.485 - max(0, 10.677 - 192.551+185.485))
=5.886

Note: The Operating Income data used here is one times the annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Hemab Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-70.119/( ( (2.567 + max(-2.689, 0)) + (1.701 + max(-5.593, 0)) )/ 2 )
=-70.119/( ( 2.567 + 1.701 )/ 2 )
=-70.119/2.134
=-3,285.80 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.327) - (4.35 + 0 + 1.666)
=-2.689

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.437) - (7.023 + 0 + 3.007)
=-5.593

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hemab Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=/2010.270
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings EBIT Related Terms

Hemab Therapeutics Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings EBIT Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
EBIT
-50.38 -70.12

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
EBIT -50.38 -70.12

COAG vs ZLAB, SLS, IOVA: EBIT Comparison

For the Biotechnology subindustry, Hemab Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemab Therapeutics Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hemab Therapeutics Holdings's EV-to-EBIT falls into.


COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $ Mil mean?
Hemab Therapeutics Holdings (COAG) has a EBIT of $ Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hemab Therapeutics Holdings.
Is Hemab Therapeutics Holdings' EBIT too high?
Hemab Therapeutics Holdings' current EBIT is $ Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' EBIT compare to ZLAB and SLS?
Hemab Therapeutics Holdings' EBIT of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hemab Therapeutics Holdings. Hemab Therapeutics Holdings's current EBIT is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current EBIT of $ Mil. The current EBIT is $ Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current EBIT is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.52
Price